Familial glucocorticoid resistance is a hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations in the absence of stigmata of Cushing's syndrome. Our previous studies of the first reported kindred showed a two-to threefold reduction in glucocorticoid receptor-ligand binding affinity in the propositus, and a lesser reduction in affinity in his mildly affected son and nephew. Glucocorticoid receptor cDNA from these three patients was amplified by polymerase chain reaction and sequenced. The cDNA nucleotide sequence was normal, except for nucleotide 2054, which substituted valine for aspartic acid at amino acid residue 641. The propositus was homozygous while the other relatives were heterozygous for the mutation. COS-7 monkey kidney cells were cotransfected with expression vectors for either wild type or Val 641-mutant receptors, together with the reporter plasmid pMMTV-CAT. Dexamethasone increased chloramphenicol acetyltransferase activity in cells expressing wild type receptor, but had no effect in cells expressing Val 641-mutant receptors, despite similar receptor concentrations, as indicated by Western blotting. The binding affinity for dexamethasone of the Val 641-mutant receptor was threefold lower than that of the wild type receptor. These results suggest that glucocorticoid resistance in this family is due to a point mutation in the steroid-binding domain of the glucocorticoid receptor. 
Introduction
The profound effects of glucocorticoid hormones on gene transcription in virtually all tissues are mediated by the glucocorticoid receptor (GR),' the prototypic member of a family of ligand-activated transcription factors homologous to the v-erb A oncogene (1) . The primary structure of the human GR (hGR) has been deduced from complementary (c) DNA cloning (2) , and the hGR gene has been localized on chromosome 5 (2, 3) . It has been suspected that a mutation in the hGR gene is responsible for the syndrome of familial glucocorticoid resistance (FGR) (4) (5) (6) (7) . In this condition, serum cortisol concentrations and cortisol production rate are greatly increased, without the characteristic clinical and biochemical stigmata of glucocorticoid excess. Plasma ACTH concentrations are also elevated, despite cortisol hypersecretion, and the hypothalamic-pituitary-adrenal axis is resistant to suppression by exogenous glucocorticoids. These changes reflect generalized tissue resistance to cortisol, which appears to be compensated for by high ACTH and cortisol concentrations (4, 5) . The high ACTH levels, however, also participate in the pathophysiology ofthe syndrome by stimulating adrenal secretion of salt-retaining hormones and androgens. These, respectively, interact with the mineralocorticoid receptor and androgen receptor, thereby causing hypertension and hypokalemic alkalosis in both sexes and/or hyperandrogenism in women (5, 8) . Male precocious puberty has also been described (9) .
We have conducted extensive studies of the large kindred, in which FGR was first described, to identify the molecular basis of the syndrome (5, 7, 10, 1). The propositus had no features of glucocorticoid excess despite a sevenfold elevation of nonprotein bound cortisol in serum and a 30-40 fold increase in urinary free cortisol excretion. The dose ofdexamethasone needed to suppress serum cortisol levels by 50% in this patient was seven times greater than in normal subjects (5) . Less severe but unequivocal cortisol excess and dexamethasone resistance were found in one son and one nephew. Borderline cortisol excess was detected in 6 of 27 additional relatives from three generations (7) , consistent with an autosomal codominant mode of inheritance in which heterozygotes are mildly affected.
The concentrations of GR in intact mononuclear leukocytes from the propositus and his mildly affected son were normal, but the affinity of ligand binding was two-to threefold lower than in cells from normal subjects (5, 1 1). Borderline decreases in affinity were also seen in his son (5, 1 1). To facilitate further studies, lymphoblast cell lines were established by Epstein-Barr virus transformation ofperipheral blood lymphocytes obtained from the propositus and from his mildly affected son and nephew (12) . GR in the lymphoblasts of these patients had similar binding properties to GR in their untransformed cells. The hormone-receptor complex ofthe propositus migrated with the expected molecular size, but exhibited increased thermolability and reduced binding to DNA cellulose after thermal activation (12) . Northern blot analysis demonstrated specific GR mRNA of the expected size (7) . It was concluded from these studies that the most likely molecular defect was a mutation of the GR gene located in the region that encodes the hormone binding domain of the receptor. In this 680 Hurley, Accili, Stratakis, Karl, Vamvakopoulos, Rorer, Constantine, Taylor, and Chrousos study, we used the polymerase chain reaction (PCR) (13) to amplify the patients' GR cDNA and identified a mutation substituting valine for Asp"' in the hormone binding domain of the receptor. This mutation causes glucocorticoid resistance with codominant inheritance.
Methods
Cell lines. EBV-transformed lymphoblast lines previously established from the propositus and his son and nephew (12, 14) were grown in RPMI 1640 medium, supplemented with 10% fetal bovine serum and 2 mM glutamine. COS-7 monkey kidney cells were grown as monolayers in Dulbecco's modified Eagle's medium (Biofluids Inc., Rockville, MD), supplemented with 10% (vol/vol) charcoal-treated fetal bovine serum (Biofluids Inc.), 100 U/ml penicillin and streptomycin and Lglutamine at 37°C in a 5% CO2 atmosphere.
Isolation ofRNA, reverse transcription, PCR amplification. Total RNA was isolated from the cultured lymphoblasts by the acid-guanidinium-thiocyanate-phenol-chloroform method (15). mRNA was obtained by oligo(dT) chromatography (New England Biolabs, Beverly, MA). Single-stranded cDNA was synthesized from total RNA Table I ). The primers were used in PCRs to synthesize double-stranded cDNA in order to obtain overlapping segments for determination of the nucleotide sequence. The location of the PCR primers and the strategy for sequencing the entire 2.3-kb coding region of the hGR are shown in Fig. 1 Restriction endonuclease digestion ofPCR-amplified cDNAs. The restriction endonuclease enzyme Mae-II (Boehringer Mannheim Biochemicals) was used to digest the 1.4-kb PCR product encoding both the ligand and DNA binding domains of the receptor cDNA from the patients (Fig. 1) . The ends ofthe generated fragments were then labeled using [a-32P]dCTP and 2 U of Klenow enzyme (labeling grade; Boehringer Mannheim Biochemicals). The resulting segments were resolved in 5% polyacrylamide gel, which was dried and exposed for 1 h to Kodak X-Omat film. The ethidium bromide-stained 1% agarose gels show that PCR amplified hGR cDNA of the three patients and normal hGR cDNA using primers 6 and 10 (left), and primers 3 and 13 (right), yielded the expected 1.2-kb and 1.4-kb fragments, respectively, excluding major deletions, insertions, or other rearrangements. Region C represents the segment of genomic DNA which was amplified from normal subjects.
Hybridization with synthetic oligonucleotides. Two synthetic oligonucleotides (1 8mers) were made, one bearing the identified base substitution (5'-CATGTACGTCCAATGTAA-3'; the T in place of the normal A at position 2054 is underlined) and the other consisting of the normal sequence 3' to the base substitution site (5'-CCAATGTAAACACATGCT-3'; nucleotides in common with the oligonucleotide bearing the base substitution are underlined (Table II) , in order to amplify the hGR cDNA region (1586-2404).
The product of the third PCR was digested with Eco RI. The Cla I-Xho I fragment (including hGR cDNA nucleotides 1526-2463) of the pRShGRa expression vector was inserted into the multiple cloning site of Bluescript plasmid (Stratagene, La Jolla, CA). After digestion of the recombinant plasmid with Eco RI, the digested PCR fragment was ligated into the plasmid to replace the wild-type sequence. Subsequently, the recombinant Cla I-Xho I fragment ofthe hGR cDNA was ligated back into the pRShGRa. Sequencing of the full length Cla IXho I insert within the hGR cDNA of the recombinant plasmid pRShGRa confirmed the presence of the mutation without any other base changes. The recombinant plasmid was designated RShGRVal 64 1. Binding assays. COS-7 cells transfected with either wild type or Val 641 -mutant GR plasmids were suspended in TEDGM buffer (10 mM Tris-HCI, 1.5 mM EDTA, 3% Glycerol, 0.5 nM dithiothreitol, and 20 nM sodium molybdate, pH 7.4) and homogenized with a teflon-coated mortar and pestle at 4°C. Cytosol was obtained by ultracentrifugation at 105,000 g at 4°C for I h. Aliquots of cytosol were incubated with
[3H]dexamethasone at four concentrations (1-20 nM) in the absence and presence of50-fold excess ofunlabeled hormone, at 4°C for 18 h to determine total and nonspecific binding, respectively. The receptorbound 3H-steroid was separated from the unbound steroid by addition of a 0.5% charcoal solution, coated with dextran (1.0%) followed by centrifugation at 3,000 rpm at 4°C for 15 min. An aliquot was counted in a 3-counter, and specific binding was calculated by subtracting nonspecific from total binding. The cytosol protein concentrations were determined using a Coomassie Protein Assay Reagent. The data was then analyzed by the method of Scatchard. Binding capacities were expressed as fmol/mg protein and Kd in mM (5 Fig. 1 ). We determined the nucleotide sequence of the coding region of GR cDNA according to a strategy summarized in Fig. 1 (Fig. 1) , was initially selected for amplification and sequencing. PCR amplification and subsequent sequencing ofthis region in both orientations was performed multiple times, with different batches of cDNA prepared from total RNA and mRNA from all three patients. There was complete concordance with the published normal nucleotide sequence, except at nucleotide 2054, where a T residue was present in place of the normal A. This base change results in a nonconservative amino acid substitution at position 641 of the hGR protein. Thus, the aspartic acid codon (GAC) was changed to a valine codon (GTC) (Fig.  2) . In the propositus, only T was identified at nucleotide 2054, suggesting that this severely affected patient was homozygous for the Val 641 mutation. The nucleotide sequences of amplified GR cDNA from the mildly affected son and nephew contained both A and T residues at position 2054, suggesting heterozygosity (Fig. 2) . To reveal other possible changes in the remaining sequence of the hGR cDNA of the three patients, the rest of the coding region of the receptor cDNA was sequenced, following a similar strategy (Fig. 1) . No other alteration was found in the full length sequence ofthe 2.3-kb coding region of the hGR cDNA in any of the three patients. positus' cDNA produced the 0.6-kb fragment, and fragments of 0.35 and 0.5 kb instead of the 0.85-kb band, confirming the sequencing results. The smaller bands as well as the 0.85-kb band were present in digests of the two relatives' amplified cDNA consistent, with the sequencing evidence of heterozygosity (Fig. 3) . Allele-specific oligonucleotide hybridization was carried out with an 1 8mer mutant nucleotide sequence to detect the mutation. PCR-amplified cDNA from the propositus, normal hGR cDNA, and genomic DNAs from normal subjects were hybridized with the probe. After washing under stringent conditions, the oligonucleotide specifically hybridized to the GR cDNA from the patient. Similar results were obtained when PCR-amplified cDNA of the other two patients were hybridized with the same 1 8mer, providing a convenient method for the identification of the mutation in subsequent experiments (data not shown).
In order to determine whether the identified base substitution is responsible for glucocorticoid resistance in this kindred, T was inserted in place of A at position 2054 of the normal hGR cDNA in the pRShGRa expression plasmid, creating pRShGRa-Val 641. COS-7 cells were then transfected with either the wild-type or Val 641-mutant plasmid, together with the MMTV-CAT reporter plasmid, in which glucocorticoid response elements (GREs) within the long terminal repeat of the mouse mammary tumor virus are coupled to the CAT gene. The ability of expressed wild type and Val 64 1-mutant hGR to interact with GRE's and thereby stimulate CAT gene expression was assessed by measuring CAT activity after exposure to increasing doses of dexamethasone. In cells transfected with wild-type plasmid, dexamethasone induced a 20-to 30-fold increase in CAT activity (Fig. 4) . However, there was no stimulation of CAT activity by dexamethasone in cells which had been transfected with the Val 64 1-mutant plasmid (Fig. 4) .
Western blots using monoclonal anti-GR antibody demonstrated similar levels of expression of both wild type and Val 641-mutant GR in transfected COS-7 cells, and confirmed that both species migrated with the expected molecular size (Fig. 5) .
Specific high affinity binding [3H] dexamethasone was demonstrated in cytosol prepared from Cos-7 cells transfected with pRShGRa (Fig. 5) . The binding capacity was (Fig. 5 ).
Discussion
Several lines of evidence indicate that the Val 641 mutation is responsible for impaired ligand binding and glucocorticoid resistance in this kindred. Firstly, the aspartate codon at position 641 lies within the cDNA region that encodes the hormone binding domain of the GR, and is absolutely conserved in the homologous positions of all species studied to date (2, 24, 25) . Interestingly, the human mineralocorticoid receptor also retains an acidic amino acid (glutamate) in this position (26) . Secondly, the aspartate residue at position 641 is adjacent to the cysteine residue at position 638 that corresponds to cysteine 656 of the rat GR, which has been shown by covalent labeling with the ligand dexamethasone 21 -mesylate to lie within the steroid binding cavity of the receptor, and to be intimately involved in hormone binding (27, 28) . Modification ofthiol groups on this and an adjacent cysteine residue causes a reduction in ligand binding affinity similar to that observed in the FGR kindred, consistent with the concept that amino acids in this region play an important role in high affinity binding. Replacement of the acidic aspartate residue at position 641 with the neutral valine residue, therefore, provides a plausible explanation for impaired ligand binding in this family. Thirdly, segregation of the allele bearing the base substitution is consistent with the conclusion that this mutation causes the glucocorticoid resistant phenotype, with the severely affected propositus being homozygous and his mildly affected relatives being heterozygous. Finally, the fact that no other change was present in the nucleotide sequence of the 2.3-kb coding region of the hGR cDNA of all three patients, strongly suggests that the identified point mutation is not a functionally insignificant polymorphism. The in vitro expression studies provided definitive confirmation that the Val 64 1-substituted GR, resulting from replacement ofA by T at nucleotide position 2054, has reduced ligand binding affinity and impaired ability to activate gene expression through glucocorticoid response elements. This base substitution is, therefore, able to account for the threefold reduction in GR ligand binding affinity and glucocorticoid resistance observed in the propositus ofthis kindred. The complete lack of CAT induction by dexamethasone in cells transfected with pRShGR-Val 641 mutant plasmid is surprising and suggests that the in vitro COS-7 cotransfection system may differ from the in vivo situation.
The absence of overt evidence of glucocorticoid deficiency in the propositus implies that the increase in plasma corticol concentrations, which occurs in FGR, restores a normal level ofglucocorticoid action. This might result from increased GRE occupancy by defective receptor-ligand complexes. Possible mechanisms for reduced transcriptional activity of the Val 64 1-mutant GR include failure of ligand binding to fully activate the receptor, resulting in reduced GRE binding affinity, impaired receptor dimerization, a process that involves regions of the ligand binding domain (29) , and reduced activity of one or more transactivation domains, including those located in the ligand binding domain (29) . Further work will be needed to distinguish between these possibilities.
Mild glucocorticoid resistance in heterozygotes may indicate that the GR produced by transcription ofthe normal allele is unable to maintain homeostasis without elevation of glucocorticoids. An interesting alternative possibility is that mutant receptors interfere with the function of normal receptors, perhaps by preventing appropriate dimerization, or by exerting antagonist effects on GREs, as has been shown for the GRdexamethasone 21-mesylate complex (30) . The fact that the GR-dexamethasone mesylate complex has antagonist properties, despite high DNA binding affinity, raises the possibility that the steroid binding domain of the hGR may also be involved in transcriptional regulation, as it has been already shown with mouse GR (31) .
Since the initial description and extensive study of this FGR kindred, members of five smaller families with the FGR syndrome have been reported (8, 9, (32) (33) (34) . The clinical presentation varied from asymptomatic to hypertension, chronic fatigue, hyperandrogenism in women, and isosexual precocity in a boy. Similarly, the glucocorticoid receptor defects identified varied markedly: decreased ligand binding affinity (5, 9) , an unstable receptor (32), decreased receptor concentration (33), and a receptor with defective nuclear binding (36) have been reported. Both autosomal recessive and autosomal dominant modes of inheritance have been proposed (8, 10) . Although detailed DNA studies have not been reported in this syndrome, it seems likely that this state may result from a number of different molecular mechanisms as in other nuclear hormone resistance syndromes (35) (36) (37) (38) (39) . Because ofthe potential clinical subtlety ofthe syndrome and the high prevalence ofits varying presentations, mild hypertension, fatigue, and hyperandrogenism, suggest that studies in these patient populations may reveal subgroups with a defined molecular pathophysiology. Direct sequencing of PCR-amplified products provides a powerful tool to identify defects at the hGR gene level. In addition, the use of restriction endonuclease enzymes and/or allele-specific hybridization with synthetic oligonucleotides provides a fast and convenient method for the identification ofcharacterGlucocorticoid 
